Associated Papers
GenoStaR: An R Package for Genotype to Star Allele Conversion for Major Cytochrome P450 Family of Genes.
Coulter AJ et al.
Clinical Pharmacology and Therapeutics, 2026
CYP1A2 expression and activity in a large panel of human nonneoplastic surgical liver samples: Influence of genetics, lifestyle, and other factors.
Kuhn UD et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2025
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia.
Vaiman EE et al.
International Journal of Molecular Sciences, 2022
CYP1A2 mRNA Expression Rather than Genetic Variants Indicate Hepatic CYP1A2 Activity.
Fekete F et al.
Pharmaceutics, 2022
Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population.
de Andrés F et al.
The Pharmacogenomics Journal, 2021
A review of the existing literature on buprenorphine pharmacogenomics.
Meaden CW et al.
The Pharmacogenomics Journal, 2021
Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2020
Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.
Na Takuathung M et al.
Acta Psychiatrica Scandinavica, 2019
Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing.
Zeier Z et al.
The American Journal of Psychiatry, 2018
Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.
Crist RC et al.
The American Journal of Drug and Alcohol Abuse, 2018
CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study.
Salinero JJ et al.
Nutrients, 2017
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer.
Garcia S et al.
Case Reports in Genetics, 2017
Genetic polymorphism analysis of the drug-metabolizing enzyme CYP1A2 in a Uyghur Chinese population: a pilot study.
Geng T et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2016
Use of combinatorial pharmacogenomic testing in two cases from community psychiatry.
Fields ES et al.
Pharmacogenomics and Personalized Medicine, 2016
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar CA et al.
The Pharmacogenomics Journal, 2015
Genetic and Clinical Factors Affecting Plasma Clozapine Concentration.
Olsson E et al.
The Primary Care Companion for Cns Disorders, 2015
Genetic polymorphisms in promoter and intronic regions of CYP1A2 gene in Roma and Hungarian population samples.
Szalai R et al.
Environmental Toxicology and Pharmacology, 2014
Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism.
Djordjevic N et al.
European Journal of Clinical Pharmacology, 2010
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.
Zhou SF et al.
Drug Metabolism Reviews, 2010
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.
Xu CF et al.
British Journal of Cancer, 2010
Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.
Zhou SF et al.
The Aaps Journal, 2009
Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers.
Ghotbi R et al.
The Pharmacogenomics Journal, 2009
Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
Gunes A et al.
Pharmacogenomics, 2009
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Ingelman-Sundberg M et al.
Pharmacology & Therapeutics, 2007
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.
Ghotbi R et al.
European Journal of Clinical Pharmacology, 2007
Investigating the phenotypes and genotypes of breast cancer in women with African ancestry: the need for more genetic epidemiology.
Hayanga AJ et al.
The Surgical Clinics of North America, 2007
Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy.
Takata K et al.
European Journal of Clinical Pharmacology, 2006
Functional analysis of three CYP1A2 variants found in a Japanese population.
Saito Y et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics.
Johnson AD et al.
Pharmacology & Therapeutics, 2005